Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:DYN NASDAQ:OLMA NASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.49$31.37$19.05▼$32.56$3.86B0.742.62 million shsN/ADYNDyne Therapeutics$23.21-2.6%$20.13$8.88▼$25.00$3.94B1.062.09 million shs9.16 million shsOLMAOlema Pharmaceuticals$11.49-0.9%$11.69$4.47▼$36.26$1.01B21.59 million shs681,569 shsRLAYRelay Therapeutics$19.27-0.2%$16.33$3.03▼$20.79$3.70B1.673.87 million shs1.32 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%0.00%+0.35%+21.40%+49.88%DYNDyne Therapeutics+1.62%+0.21%+20.35%+21.15%+159.87%OLMAOlema Pharmaceuticals+2.11%-2.19%+21.87%-28.63%+152.51%RLAYRelay Therapeutics+0.63%+1.15%+21.54%+16.90%+431.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.49$31.37$19.05▼$32.56$3.86B0.742.62 million shsN/ADYNDyne Therapeutics$23.21-2.6%$20.13$8.88▼$25.00$3.94B1.062.09 million shs9.16 million shsOLMAOlema Pharmaceuticals$11.49-0.9%$11.69$4.47▼$36.26$1.01B21.59 million shs681,569 shsRLAYRelay Therapeutics$19.27-0.2%$16.33$3.03▼$20.79$3.70B1.673.87 million shs1.32 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%0.00%+0.35%+21.40%+49.88%DYNDyne Therapeutics+1.62%+0.21%+20.35%+21.15%+159.87%OLMAOlema Pharmaceuticals+2.11%-2.19%+21.87%-28.63%+152.51%RLAYRelay Therapeutics+0.63%+1.15%+21.54%+16.90%+431.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.56Moderate Buy$32.001.62% UpsideDYNDyne Therapeutics 2.86Moderate Buy$34.1747.21% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.10283.81% UpsideRLAYRelay Therapeutics 3.00Buy$24.9229.30% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, DYN, CPRX, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026RLAYRelay Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $31.007/17/2026DYNDyne Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026RLAYRelay Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.007/16/2026RLAYRelay Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.007/8/2026RLAYRelay Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$28.007/6/2026RLAYRelay Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/26/2026DYNDyne Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/3/2026CPRXCatalyst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/28/2026CPRXCatalyst Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/26/2026RLAYRelay Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $26.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$596.96M6.46$2.92 per share10.77$7.76 per share4.06DYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/ARLAYRelay Therapeutics$15.35M240.52N/AN/A$3.27 per share5.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.7418.1010.220.9637.08%35.76%31.31%8/5/2026 (Estimated)DYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$2.02N/AN/AN/AN/A-46.00%-41.22%8/10/2026 (Estimated)RLAYRelay Therapeutics-$276.48M-$1.57N/AN/AN/AN/A-43.94%-40.11%8/6/2026 (Estimated)Latest OLMA, DYN, CPRX, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026OLMAOlema Pharmaceuticals-$0.53N/AN/AN/AN/AN/A8/6/2026Q2 2026RLAYRelay Therapeutics-$0.41N/AN/AN/A$0.96 millionN/A8/5/2026Q2 2026CPRXCatalyst Pharmaceuticals$0.48N/AN/AN/A$155.79 millionN/A7/27/2026Q2 2026DYNDyne Therapeutics-$0.74N/AN/AN/AN/AN/A5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52-$0.52N/A-$0.52N/AN/A5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/5/2026Q1 2026RLAYRelay Therapeutics-$0.35-$0.41-$0.06-$0.41$5.58 million$3.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A7.106.84DYNDyne Therapeutics0.1719.9219.92OLMAOlema Pharmaceuticals0.0110.8810.88RLAYRelay TherapeuticsN/A22.1322.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%DYNDyne Therapeutics96.68%OLMAOlema Pharmaceuticals91.78%RLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%DYNDyne Therapeutics9.46%OLMAOlema Pharmaceuticals12.56%RLAYRelay Therapeutics5.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.42 million109.69 millionOptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableOLMAOlema Pharmaceuticals7087.35 million76.38 millionOptionableRLAYRelay Therapeutics330191.59 million181.93 millionOptionableOLMA, DYN, CPRX, and RLAY HeadlinesRecent News About These CompaniesRelay Therapeutics (NASDAQ:RLAY) Research Coverage Started at Canaccord Genuity GroupJuly 19 at 1:43 AM | americanbankingnews.comRelay Therapeutics (NASDAQ:RLAY) Raised to "Strong-Buy" at Canaccord Genuity GroupJuly 17, 2026 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Buy" from BrokeragesJuly 15, 2026 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Buy" by AnalystsJuly 15, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 7.4% - Here's What HappenedJuly 13, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells $162,028.60 in StockJuly 9, 2026 | insidertrades.comRelay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 8,660 Shares of StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of StockJuly 8, 2026 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) CEO Sells $943,736.42 in StockJuly 8, 2026 | marketbeat.comInsider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 50,000 Shares of StockJuly 3, 2026 | insidertrades.comRelay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past YearJune 29, 2026 | fool.comRelay Therapeutics (NASDAQ:RLAY) Insider Sells 93,456 Shares of StockJune 25, 2026 | insidertrades.comRelay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is WhyJune 11, 2026 | insidermonkey.comRelay Therapeutics Expands Authorized Shares at 2026 MeetingJune 9, 2026 | tipranks.comRelay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Jefferies Global Healthcare Conference 2026 TranscriptJune 3, 2026 | seekingalpha.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 27, 2026 | globenewswire.comRelay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - SlideshowMay 22, 2026 | seekingalpha.comRelay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data ReleaseMay 22, 2026 | finance.yahoo.comRelay Therapeutics prices $275M public offering of common stock at $12/shareMay 21, 2026 | msn.comRelay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)May 21, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026These 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialBy Nathan Reiff | July 8, 2026Prepare for the Next Wave of Factory Automation With These 3 Standout NamesBy Nathan Reiff | July 14, 2026OLMA, DYN, CPRX, and RLAY Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.49 0.00 (0.00%) As of 07/16/2026Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Dyne Therapeutics NASDAQ:DYN$23.21 -0.62 (-2.60%) Closing price 04:00 PM EasternExtended Trading$23.17 -0.04 (-0.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$11.49 -0.10 (-0.86%) Closing price 04:00 PM EasternExtended Trading$11.50 +0.00 (+0.04%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Relay Therapeutics NASDAQ:RLAY$19.27 -0.03 (-0.16%) Closing price 04:00 PM EasternExtended Trading$18.85 -0.42 (-2.18%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
